Supernus Pharmaceuticals to report Q3 2026 results
Item 2.02 Reports results
- Form
- 8-K
- Filed
- Importance
- Major
- Accession
- 0001356576-26-000043
- Q3 2026 results to be reported after market close on Oct 29, 2026
- Conference call scheduled for Oct 29, 2026 at 4:30 p.m. E.T.
Written from the 8-K on EDGAR. Check the filing before you rely on it.
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Sarepta Therapeutics SRPT public float $1.7B, Jun 30, 2025
- Amicus Therapeutics FOLD public float $1.7B, Jun 30, 2025
- Ocular Therapeutix OCUL public float $1.6B, Jun 30, 2025
- Ligand Pharmaceuticals LGND public float $1.6B, Jun 30, 2025
- Apellis Pharmaceuticals APLS public float $1.8B, Jun 30, 2025